Arachidonic and docosahexaenoic acid supplementation and brain maturation in preterm infants; a double blind RCT.
Arachidonic acid
Brain
Docosahexaenoic acid
Fatty acid supplementation
Neurodevelopment
Preterm
Journal
Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603
Informations de publication
Date de publication:
29 Nov 2023
29 Nov 2023
Historique:
received:
25
08
2023
revised:
24
11
2023
accepted:
26
11
2023
medline:
8
12
2023
pubmed:
8
12
2023
entrez:
7
12
2023
Statut:
aheadofprint
Résumé
Arachidonic acid (ARA) and docosahexaenoic acid (DHA) are important structural components of neural cellular membranes and possess anti-inflammatory properties. Very preterm infants are deprived of the enhanced placental supply of these fatty acids, but the benefit of postnatal supplementation on brain development is uncertain. The aim of this study was to test the hypothesis that early enteral supplementation with ARA and DHA in preterm infants improves white matter (WM) microstructure assessed by diffusion-weighted MRI at term equivalent age. In this double-blind, randomized controlled trial, infants born before 29 weeks gestational age were allocated to either 100 mg/kg ARA and 50 mg/kg DHA (ARA:DHA group) or medium chain triglycerides (control). Supplements were started on the second day of life and provided until 36 weeks postmenstrual age. The primary outcome was brain maturation assessed by diffusion tensor imaging (DTI) using Tract-Based Spatial Statistics (TBSS) analysis. We included 120 infants (60 per group) in the trial; mean (range) gestational age was 26 This study suggests that supplementation with ARA and DHA at doses matching estimated fetal accretion rates improves WM maturation compared to control treatment, but further studies are needed to ascertain any functional benefit. www. gov; ID:NCT03555019.
Sections du résumé
BACKGROUND
BACKGROUND
Arachidonic acid (ARA) and docosahexaenoic acid (DHA) are important structural components of neural cellular membranes and possess anti-inflammatory properties. Very preterm infants are deprived of the enhanced placental supply of these fatty acids, but the benefit of postnatal supplementation on brain development is uncertain. The aim of this study was to test the hypothesis that early enteral supplementation with ARA and DHA in preterm infants improves white matter (WM) microstructure assessed by diffusion-weighted MRI at term equivalent age.
METHODS
METHODS
In this double-blind, randomized controlled trial, infants born before 29 weeks gestational age were allocated to either 100 mg/kg ARA and 50 mg/kg DHA (ARA:DHA group) or medium chain triglycerides (control). Supplements were started on the second day of life and provided until 36 weeks postmenstrual age. The primary outcome was brain maturation assessed by diffusion tensor imaging (DTI) using Tract-Based Spatial Statistics (TBSS) analysis.
RESULTS
RESULTS
We included 120 infants (60 per group) in the trial; mean (range) gestational age was 26
CONCLUSION
CONCLUSIONS
This study suggests that supplementation with ARA and DHA at doses matching estimated fetal accretion rates improves WM maturation compared to control treatment, but further studies are needed to ascertain any functional benefit.
CLINICAL TRIAL REGISTRATION
BACKGROUND
www.
CLINICALTRIALS
RESULTS
gov; ID:NCT03555019.
Identifiants
pubmed: 38061271
pii: S0261-5614(23)00416-8
doi: 10.1016/j.clnu.2023.11.037
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT03555019']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
176-186Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.